Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
Open Access
- 2 November 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (5), 2165-2173
- https://doi.org/10.1182/blood-2006-06-028092
Abstract
The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears aKeywords
This publication has 74 references indexed in Scilit:
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- Inhibition of Phosphatidylinositol 3′-Kinase/AKT Signaling Promotes Apoptosis of Primary Effusion Lymphoma CellsClinical Cancer Research, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004
- Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcomaNature Genetics, 2004
- Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirusNature Genetics, 2004
- 4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to RapamycinJournal of Biological Chemistry, 2002
- Transmission of Human Herpesvirus 8 Infection from Renal-Transplant Donors to RecipientsNew England Journal of Medicine, 1998
- Human Interferon-γ–inducible Protein 10 (IP-10) Inhibits Constitutive Signaling of Kaposi's Sarcoma–associated Herpesvirus G Protein–coupled ReceptorThe Journal of Experimental Medicine, 1998
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994